Clinical Trial Update: Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is exploring optimization of multidrug-resistant tuberculosis treatment based on molecular drug susceptibility results for pyrazinamide…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multidrug-resistant Tuberculosis

Drugs mentioned

• Pyrazinamide (pyrazinamide)

Snippet

Sponsor: Huashan Hospital | Conditions: Multidrug Resistant Tuberculosis | Phase 3 | Status: UNKNOWN